SCHEMBL9023602

SCHEMBL9023602

C#CCC(C(C)=O)C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 2/20 0.34
TDP1 Q9NUW8 2/20 0.33
ALOX15 P16050 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SOAT1 P35610 1/20 0.33
MMP8 P22894 1/20 0.33
POLB P06746 1/20 0.32
GLO1 Q04760 1/20 0.31
TRPA1 O75762 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5804056 0.90 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL9188359 0.83 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL8808086 0.82 ACHE (0.34) ALDH1A1MGAMGAASIMGAM2
SCHEMBL5143738 0.81 ALDH1A1 (0.36) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL435187 0.80 GRIK1 (0.35)
SCHEMBL20522498 0.80 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL5141898 0.78 GAA (0.47) ALDH1A1LMNATSHRTDP1ALOX15
SCHEMBL20184104 0.78 CYP1A2 (0.35) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL10510357 0.77 ALDH1A1 (0.33) ALDH1A1LMNAHSD17B10TSHRTDP1
SCHEMBL28017515 0.77 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV OF MARYLAND BALTIMORE (US) 2026-05-21 US disclosed
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-08-05 US disclosed
EP-3423452-B1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV MARYLAND (US) 2025-05-07 EP disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 US disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-01-05 US disclosed
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2020-09-24 US disclosed
US-10723715-B2 2020-07-28 US disclosed
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
EP-0611368-B1 SUBSTITUTED AMINOPYRIMIDINES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PROD (US) 1996-02-07 EP disclosed
EP-0611368-A1 SUBSTITUTED AMINOPYRIMIDINES AS ANGIOTENSINE II ANTAGONISTS. AMERICAN HOME PROD (US) 1994-08-24 EP disclosed
US-5336677-A ANTAGONIST OF ANGIOTENSIN II AMERICAN HOME PRODUCTS CORPORATION (US) 1994-08-09 US disclosed
WO-1993008169-A1 SUBSTITUTED AMINOPYRIMIDINES AS ANGIOTENSINE II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
EP-0046677-B1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-07-24 EP disclosed
US-4487626-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-12-11 US disclosed
EP-0057546-A2 Sulfonylurea N-oxides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-08-11 EP disclosed
EP-0046677-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A ALDH1A1 4413/4885LMNA 1656/4885HSD17B10 1708/4885
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A ALDH1A1 4413/4885LMNA 1656/4885HSD17B10 1708/4885
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A ALDH1A1 4413/4885LMNA 1656/4885HSD17B10 1708/4885
US-20140275092-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM1B, DOT1L, EHMT1 ALDH1A1 423/4885LMNA 2354/4885HSD17B10 1115/4885
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A ALDH1A1 4413/4885LMNA 1656/4885HSD17B10 1708/4885
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE CTNNB1, WNT1, CTNND1 ALDH1A1 3230/4885LMNA 1227/4885HSD17B10 1206/4885
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A ALDH1A1 4413/4885LMNA 1656/4885HSD17B10 1708/4885
US-10723715-B2 CTNNB1, WNT1, CTNNBL1 ALDH1A1 3391/4885LMNA 920/4885HSD17B10 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.